DiaMedica Therapeutics In... (DMAC)
| Bid | 3.1 |
| Market Cap | 179.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.44M |
| EPS (ttm) | -0.6 |
| PE Ratio (ttm) | -6.98 |
| Forward PE | -5.67 |
| Analyst | Strong Buy |
| Ask | 5 |
| Volume | 62,580 |
| Avg. Volume (20D) | 92,198.4 |
| Open | 4.21 |
| Previous Close | 4.15 |
| Day's Range | 4.02 - 4.21 |
| 52-Week Range | 2.14 - 6.82 |
| Beta | 1.49 |
About DMAC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic ...
Analyst Forecast
According to 2 analyst ratings, the average rating for DMAC stock is "Strong Buy." The 12-month stock price forecast is $8, which is an increase of 90.93% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
DiaMedica Therapeutics Inc. (DMAC) Q4 2024 Earnings Call TranscriptDiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Rick Pauls - President and CEO Lorianne Masuoka - CMO Scott Kellen - CFO Conf...
2 months ago · businesswire.com
DiaMedica Therapeutics Appoints Daniel J. O'Connor to the Board of DirectorsMINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the election of ...
